Xiangqian Zheng-Xiangqian
Department Of Thyroid And Neck Tumor
Tianjin, 300060, China
Tianjin, 300060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.
Journal: Investigational new drugs
Published: May 05, 2026
Prognostic value and therapeutic potential of the cuproptosis-related gene LOXL2 in thyroid cancer.
Journal: Translational oncology
Published: March 09, 2026
Papillary thyroid cancer in black thyroid: A case report.
Journal: Oral oncology
Published: May 05, 2025
Identification of stemness subtypes and prognostic modeling in thyroid cancer: the critical role of DPYSL3 in tumor progression and immune microenvironment.
Journal: Discover oncology
Published: March 05, 2025
Comprehensive Insights into APOBEC Mutations in Thyroid Cancer: Prognostic and Therapeutic Discoveries.
Journal: Biological procedures online
Published: March 02, 2025
Enhancer hijacking drives FAM20C expression to promote papillary thyroid cancer progression.
Journal: Cancer gene therapy
Published: January 24, 2025
The SOX12-YBX1-LDHA signaling axis drives metastasis in papillary thyroid carcinoma.
Journal: Cell death & disease
Published: October 30, 2024
METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer.
Journal: Cell death and differentiation
Published: January 31, 2023
Last Updated: 09/26/2026